Mid cap News

Investors responded by aggressively selling the stocks as concerns mounted over their near-term outlook.

Morningstar maintained a ‘No Moat’ view, citing low telehealth barriers and offerings rivals can replicate “with relative ease.”

Rocket Lab could gain from more NASA launch and space-systems work, while AST SpaceMobile may benefit from broader space-sector momentum.

Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.

New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.

The Cheesecake Factory stock crossed $100 for the first time.

Investors looked at the chances of a short squeeze, new defense deals, company acquisitions, and Ondas’ growing autonomous technology business.

The UAE becomes Anktiva’s fifth regulatory jurisdiction, expanding its footprint to 34 countries and boosting ImmunityBio’s global push.

The company is under pressure from insider sales and valuation concerns, even as it pins its hopes on growth in QNX and AlloyKore.

Investors are also watching for partnership or buyout catalysts as ImmunityBio expands Anktiva internationally and builds its global NK-cell platform.

An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.

Investors shifted away from capital-intensive AI and clean-energy stocks amid profitability concerns.

BlackRock disclosed ownership of 26.5 million HIMS shares, representing a stake of about 12%.

Galaxy CEO Mike Novogratz said the deal reflects its view that AI compute demand is a structural shift.

Amkor stock falls premarket after weaker Q3 revenue guidance offsets earnings beat.

Nio bought about 18.24 million CXMT shares through Nio Power Technology, with the position subject to an 18-month lockup.

Pentagon official warns about lagging U.S. drone production.

Paramount Skydance’s merger with Warner Bros. Discovery faces opposition as actors warn it could hurt jobs, reduce competition, and limit creative choices for audiences.

Wall Street turned more cautious, with Roth, B. Riley and Cantor flagging elevated approval risk.

Benchmark said multiple quantum hardware platforms can succeed as enterprise adoption expands, reducing the likelihood of a single dominant player emerging.

The expanded agreement will integrate D-Wave's quantum technology into AT&T's AI-powered network operations to tackle complex optimization challenges.

The dispute comes as Gemini faces pressure from investors, with Truist cutting its price target and the company continuing its post-restructuring focus on the US market

Morningstar similarly called Starlink a “niche solution, not a telecom disruptor,” with a realistic $129 billion global market.

An FDA advisory panel backed six of seven peptides for possible inclusion on the 503A compounding list, with Emideltide the only rejection.

IMAX, JPMorgan Chase and CSX jumped to 52-week highs on Friday amid growing Wall Street optimism after all companies posted strong Q2 results last week.

Investors are becoming more careful with companies that promise future growth but have little short-term cash flow.

The bill’s biggest obstacle, ethics rules involving President Trump’s crypto holdings, was recently cleared with a White House-backed compromise.

According to TheFly, Roth Capital raised its price target on MaxLinear to $100 from $60 while maintaining a ‘Buy’ rating.

Goldman Sachs raised its price target to $42 while keeping a ‘Neutral’ rating and highlighting execution risks.

T-Mobile called satellite service a complement to cellular networks and said it could become “table stakes.”

ASTS recently raised $1.15 billion to support growth and secure launch capacity as it remains heavily reliant on SpaceX.

Deckers’ slowing sales growth and margin concerns dominated first-quarter earnings beat.

Investors rewarded strong execution, improving profits and raised outlook.

Leerink sees a $2.2 billion peptide market, with Hims potentially capturing about 20%.

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

Red Cat faces pressure from executive turmoil, lawsuit, insider selling, and weak performance and investor concerns ahead of Q2 earnings.

Investors reacted to enterprise spending delays, healthcare competition, and weakening consumer demand.

QuantumScape’s second-quarter net loss narrowed, but adjusted EBITDA was nearly flat, indicating limited improvement in profit.

Infleqtion received three Department of Energy research projects and led gains among the companies tied to the initiative.

The company said it will continue hiring in strategic areas despite the layoffs.

The binding agreement formalizes a partnership first announced in 2025 and paves the way for Joby to launch electric air taxi services through Virgin Atlantic's booking channels.

VinFast targets at least 300,000 global deliveries this year, up from about 200,000 in 2025.

Morgan Stanley believes GeniTech’s standalone debut could help investors view Nio as more than a cash-intensive EV manufacturer.

The new panelists bring expertise in neurology, pain, dermatology, gastroenterology, addiction, cancer pharmacology and patient advocacy.

Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand.

During an interview with The Knowledge Project podcast, Nejatian said bringing employees back to the office was only the beginning of a broader cultural reset.

A proposed merger between Twenty One Capital, Strike and Bitcoin miner Elektron Energy has been abandoned, Bloomberg reported.

Sentiment improved as the company raised its fiscal 2026 profit outlook.

Investors expect stronger demand for domestic producers of rare earths and strategic materials.

Nio, Onvo and Firefly crossed 150,000 combined deliveries in Shanghai.